Study Title
A Phase 2/3 Postexposure Prophylaxis Study of PF-07321332/Ritonavir in Household Contacts of a Patient with COVID-19. (Pfizer 1006)
Purpose
To compare the efficacy of 5-day and 10-day regimens of PF-07321332/ritonavir versus placebo in preventing symptomatic RT-PCR+ SARS-CoV-2 infection in adult participants who are household contacts of a patient recently diagnosed with symptomatic Covid 19.
Eligibility
Criteria:
1. At least 18 years old.
2. No current symptoms of Covid-19/
You cannot:
Have received Covid vaccine within 6 months prior to screening.
Have a history of Covid-19 within 6 months of screening.
Have fever or any other symptoms of Covid-19
Have liver or kidney disease.
Have any other current infection.
Have cancer.
Study Process
Study process:
1. Nasopharyngeal swabs and lab drawn at select visits.
2. Patient stipend.
3. No cost of drug to patient or insurance.
4. Free Covid-19 testing.
Interested in more information on clinical research? Contact WK Health System Clinical Research Department 318-212-8130
Trial Details
Investigator:
Joseph Bocchini, M.D.
IRB:
Advarra Institutional Review Board
IRB Number:
Trial Type:
Drug
Sponsor:
Pfizer
Contact Information: